Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

milestones and reimbursements earned through the company's Wyeth

collaboration

-- Total operating expenses - $55 million to $60 million

-- Operating cash requirements - $28 million to $32 million

Conference Call Details

Trubion will host a conference call and webcast to discuss its third quarter 2007 financial results. The call will be held today at 2 p.m. Pacific Time; 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling 1-888-208-1386 or 913-981-5593. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4262106. The webcast replay will be available in the events section of Trubion's Web site.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... CA (PRWEB) July 23, 2014 ... cell therapy in the US aimed at improving the ... their newest clinical study for Parkinson’s disease. StemGenex ... of stem cell therapy are paramount when providing care ... clinical study makes stem cell therapy accessible to the ...
(Date:7/23/2014)... , July 23, 2014 ... ), the global specialty biopharmaceutical company, and ArmaGen, ... a worldwide licensing and collaboration agreement for AGT-182, ... potential treatment of both the central nervous system ... syndrome (MPS II). This collaboration strengthens Shire,s rare ...
(Date:7/23/2014)... N.J. (PRWEB) July 23, 2014 ... Comprehensive Cancer Center has joined its Strategic Alliance ... Strategic Alliance Partnership program, UNC Lineberger will have ... to raise awareness of its cutting-edge research initiatives, ... from UNC Lineberger will work with OncLive to ...
(Date:7/22/2014)... 22, 2014 The Board of Directors of BD ... declared a quarterly dividend of 54.5 cents per common share ... September 9, 2014. The indicated annual dividend rate is $2.18 ... is a leading medical technology company that partners with customers ... and evolving health needs. Our innovative solutions are focused on ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... , CORALVILLE, Iowa, Nov. 17 Vivakor, Inc. (OTC ... approved a dividend of shares of common stock of HealthAmerica, ... of the outstanding common stock. Each Vivakor shareholder will ... for each share of Vivakor common stock beneficially owned on ...
... Neuralstem, Inc. (NYSE Amex: CUR ) today provided a financial ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) , ... loss of $5,096,983, or $0.15 per share, compared with a net ... period. The increase was due to a non-cash charge related to ...
... LEIDEN, The Netherlands, November 17 ... with Actelion Pharmaceuticals Ltd,Erasmus Medical Centre and Maastricht ... hypertension (high blood pressure) and associated vascular,complications such as ... novel action mechanisms, new drugs may be discovered with,the ...
Cached Biology Technology:Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications 2
(Date:7/23/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
(Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
(Date:7/23/2014)... Scientists with the NH Agricultural Experiment Station are working ... after new research based on genetic monitoring has found ... New England have become more isolated and seen a ... endangered New England cottontail is now is at risk ... Agricultural Experiment Station researchers at the University of New ...
Breaking Biology News(10 mins):Nano-sized chip "sniffs out" explosives far better than trained dogs 2UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
... The ubiquitous and usually harmless E. coli bacterium, which ... has more than 1,000 of them involved in metabolism ... genes would theoretically be capable of generating a huge ... report in the Dec. 27 issue of Proceedings of ...
... medical doctor. Yet he is seen as a hero by ... was diagnosed with terminal lung cancer. , "In 2000 he ... months to live," said Pardini, a professor of biochemistry and ... University of Nevada, Reno. "But five years later, he ...
... great challenges for treating Parkinson's diseases and other neurodegenerative disorders ... , The brain is a complex organ with many different ... a protective barrier erected by blood vessels and glial cells ... the delivery of most drugs from the bloodstream. , But ...
Cached Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... AmpliTaq DNA Polymerase is ... the PCR process, a testimony to its ... activity profile makes it ideal for PCR ... to guarantee reproducible results. ,, AmpliTaq ...
Biology Products: